{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:00:53Z","timestamp":1791928853559,"version":"4.3.4"},"reference-count":68,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"5","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest. Ophthalmol. Vis. Sci."],"published-print":{"date-parts":[[2025,5,7]]},"DOI":"10.1167\/iovs.66.5.15","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T11:53:50Z","timestamp":1746618830000},"page":"15","source":"Crossref","is-referenced-by-count":11,"title":["Glucagon-Like Peptide 1 Receptor Agonist Stimulation Inhibits Laser-Induced Choroidal Neovascularization by Suppressing Intraocular Inflammation"],"prefix":"10.1167","volume":"66","author":[{"given":"Akira","family":"Machida","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Nagasaki Prefecture, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Radiation Medical Sciences, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Nagasaki Prefecture, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Department of Radiation Medical Sciences, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Nagasaki Prefecture, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sugao","family":"Miyagi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Nagasaki Prefecture, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Maekawa","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Nagasaki Prefecture, Japan"},{"name":"Department of Ophthalmology, National Hospital Organization Nagasaki Medical Center, Nagasaki, Nagasaki Prefecture, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuya","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Nagasaki Prefecture, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Uematsu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Nagasaki Prefecture, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kitaoka","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Nagasaki Prefecture, Japan"},{"name":"Department of Ophthalmology, Syunkai-kai Inoue Hospital Eye Center, Nagasaki, Nagasaki Prefecture, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Oishi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Nagasaki Prefecture, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1001\/jama.291.15.1900","article-title":"Age-related macular degeneration is the leading cause of blindness","volume":"291","author":"Bressler","year":"2004","journal-title":"JAMA"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1056\/NEJMra062326","article-title":"Age-related macular degeneration","volume":"355","author":"de Jong","year":"2006","journal-title":"N Engl J Med"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","article-title":"Age-related macular degeneration","volume":"379","author":"Lim","year":"2012","journal-title":"Lancet"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"bib6","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial","volume":"119","author":"Investigators","year":"2012","journal-title":"Ophthalmology"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Falavarjani","year":"2013","journal-title":"Eye (Lond)"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.ophtha.2018.01.022","article-title":"Endophthalmitis after intravitreal injection of vascular endothelial growth factor inhibitors: management and visual outcomes","volume":"125","author":"Xu","year":"2018","journal-title":"Ophthalmology"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ajo.2020.05.029","article-title":"Cost-utility analysis of VEGF inhibitors for treating neovascular age-related macular degeneration","volume":"218","author":"Brown","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"6515","DOI":"10.1016\/S0021-9258(19)69015-0","article-title":"Pancreatic pre-proglucagons are encoded by two separate mRNAs","volume":"256","author":"Lund","year":"1981","journal-title":"J Biol Chem"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1007\/BF00291980","article-title":"Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets","volume":"28","author":"Schmidt","year":"1985","journal-title":"Diabetologia"},{"key":"bib14","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","article-title":"Glucagon-like peptide-1 7-36: a physiological incretin in man","volume":"2","author":"Kreymann","year":"1987","journal-title":"Lancet"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","article-title":"Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects","volume":"44","author":"Deacon","year":"1995","journal-title":"Diabetes"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/path.5056","article-title":"The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease","volume":"245","author":"Batista","year":"2018","journal-title":"J Pathol"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"e0198938","DOI":"10.1371\/journal.pone.0198938","article-title":"Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells","volume":"13","author":"Lu","year":"2018","journal-title":"PLoS One"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/bph.15485","article-title":"Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligands","volume":"179","author":"Tanday","year":"2022","journal-title":"Br J Pharmacol"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2337\/db15-0443","article-title":"Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes","volume":"65","author":"Hernandez","year":"2016","journal-title":"Diabetes"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.7150\/ijms.20962","article-title":"GLP-1 treatment improves diabetic retinopathy by alleviating autophagy through GLP-1R-ERK1\/2-HDAC6 signaling pathway","volume":"14","author":"Cai","year":"2017","journal-title":"Int J Med Sci"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1111\/dom.13339","article-title":"Glucagon-like peptide-1 receptor expression in the human eye","volume":"20","author":"Hebsgaard","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"bib25","doi-asserted-by":"crossref","first-page":"975032","DOI":"10.1155\/2013\/975032","article-title":"Retinal pigment epithelial cells express a functional receptor for glucagon-like peptide-1 (GLP-1)","volume":"2013","author":"Puddu","year":"2013","journal-title":"Mediators Inflamm"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"H1214","DOI":"10.1152\/ajpheart.00316.2016","article-title":"GLP-1 inhibits VEGFA-mediated signaling in isolated human endothelial cells and VEGFA-induced dilation of rat mesenteric arteries","volume":"311","author":"Egholm","year":"2016","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1167\/iovs.09-4727","article-title":"Intravitreal injection of exendin-4 analogue protects retinal cells in early diabetic rats","volume":"52","author":"Zhang","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib28","first-page":"1557","article-title":"Exendin-4 protects retinal cells from early diabetes in Goto-Kakizaki rats by increasing the Bcl-2\/Bax and Bcl-xL\/Bax ratios and reducing reactive gliosis","volume":"20","author":"Fan","year":"2014","journal-title":"Mol Vis"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.exer.2016.05.002","article-title":"The glucagon like peptide 1 analogue, exendin-4, attenuates oxidative stress-induced retinal cell death in early diabetic rats through promoting Sirt1 and Sirt3 expression","volume":"151","author":"Zeng","year":"2016","journal-title":"Exp Eye Res"},{"key":"bib30","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3390\/jcm8030339","article-title":"New insights into the mechanisms of action of topical administration of GLP-1 in an experimental model of diabetic retinopathy","volume":"8","author":"Sampedro","year":"2019","journal-title":"J Clin Med"},{"key":"bib31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuropharm.2019.04.018","article-title":"Topical ocular administration of the GLP-1 receptor agonist liraglutide arrests hyperphosphorylated tau-triggered diabetic retinal neurodegeneration via activation of GLP-1R\/Akt\/GSK3\u00df signaling","volume":"153","author":"Shu","year":"2019","journal-title":"Neuropharmacology"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ajpath.2020.01.011","article-title":"The anti-inflammatory effects of glucagon-like peptide receptor agonist lixisenatide on the retinal nuclear and nerve fiber layers in an animal model of early type 2 diabetes","volume":"190","author":"Chung","year":"2020","journal-title":"Am J Pathol"},{"key":"bib33","doi-asserted-by":"publisher","first-page":"e0167853","DOI":"10.1371\/journal.pone.0167853","article-title":"The DPP4 inhibitor linagliptin protects from experimental diabetic retinopathy","volume":"11","author":"Dietrich","year":"2016","journal-title":"PLoS One"},{"key":"bib34","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1007\/s00125-018-4701-4","article-title":"Anti-angiogenic effects of the DPP-4 inhibitor linagliptin via inhibition of VEGFR signalling in the mouse model of oxygen-induced retinopathy","volume":"61","author":"Kolibabka","year":"2018","journal-title":"Diabetologia"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1167\/iovs.15-19006","article-title":"Protective effect of a GLP-1 analog on ischemia-reperfusion induced blood-retinal barrier breakdown and inflammation","volume":"57","author":"Goncalves","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib36","doi-asserted-by":"publisher","first-page":"e93382","DOI":"10.1172\/jci.insight.93382","article-title":"Myeloid cell modulation by a GLP-1 receptor agonist regulates retinal angiogenesis in ischemic retinopathy","volume":"6","author":"Zhou","year":"2021","journal-title":"JCI Insight"},{"key":"bib37","doi-asserted-by":"crossref","first-page":"3094642","DOI":"10.1155\/2016\/3094642","article-title":"Anti-inflammatory effects of GLP-1-based therapies beyond glucose control","volume":"2016","author":"Lee","year":"2016","journal-title":"Mediators Inflamm"},{"key":"bib38","doi-asserted-by":"publisher","first-page":"F1000","DOI":"10.12688\/f1000research.20602.1","article-title":"Recent advances in understanding the role of glucagon-like peptide 1","volume":"9","author":"Reed","year":"2020","journal-title":"F1000Res"},{"key":"bib39","doi-asserted-by":"publisher","first-page":"12428","DOI":"10.3390\/ijms232012428","article-title":"Anti-inflammatory effects of GLP-1R activation in the retina","volume":"23","author":"Puddu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"bib40","doi-asserted-by":"publisher","first-page":"300060521992981","DOI":"10.1177\/0300060521992981","article-title":"GLP-1 alleviates NLRP3 inflammasome-dependent inflammation in perivascular adipose tissue by inhibiting the NF-kappaB signalling pathway","volume":"49","author":"Chen","year":"2021","journal-title":"J Int Med Res"},{"key":"bib41","doi-asserted-by":"publisher","first-page":"102003","DOI":"10.1016\/j.pupt.2021.102003","article-title":"Glucagon-like peptide 1 receptor (GLP-1R) agonist relieved asthmatic airway inflammation via suppression of NLRP3 inflammasome activation in obese asthma mice model","volume":"67","author":"Hur","year":"2021","journal-title":"Pulm Pharmacol Ther"},{"key":"bib42","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.celrep.2013.08.002","article-title":"NLRP3 inflammasome blockade inhibits VEGF-A-induced age-related macular degeneration","volume":"4","author":"Marneros","year":"2013","journal-title":"Cell Rep"},{"key":"bib43","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1167\/iovs.12-10655","article-title":"NLRP3 inflammasome activation in retinal pigment epithelial cells by lysosomal destabilization: implications for age-related macular degeneration","volume":"54","author":"Tseng","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib44","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/febs.16278","article-title":"Role of inflammasome activation in neovascular age-related macular degeneration","volume":"290","author":"Marneros","year":"2021","journal-title":"FEBS J"},{"key":"bib45","doi-asserted-by":"publisher","first-page":"e69552","DOI":"10.1371\/journal.pone.0069552","article-title":"Choroid sprouting assay: an ex vivo model of microvascular angiogenesis","volume":"8","author":"Shao","year":"2013","journal-title":"PLoS One"},{"key":"bib46","first-page":"61677","article-title":"An ex vivo choroid sprouting assay of ocular microvascular angiogenesis","volume":"162","author":"Tomita","year":"2020","journal-title":"J Vis Exp"},{"key":"bib47","doi-asserted-by":"publisher","first-page":"184","DOI":"10.5812\/ijem.8088","article-title":"Liraglutide improves the survival of INS-1 cells by promoting macroautophagy","volume":"11","author":"Jing Yin","year":"2013","journal-title":"Int J Endocrinol Metab"},{"key":"bib48","doi-asserted-by":"publisher","first-page":"e97554","DOI":"10.1371\/journal.pone.0097554","article-title":"Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism","volume":"9","author":"Krasner","year":"2014","journal-title":"PLoS One"},{"key":"bib49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0022-1759(89)90178-6","article-title":"The liposome-mediated macrophage 'suicide' technique","volume":"124","author":"Van Rooijen","year":"1989","journal-title":"J Immunol Methods"},{"key":"bib50","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0923-2494(92)80169-L","article-title":"Liposome-mediated elimination of macrophages","volume":"143","author":"van Rooijen","year":"1992","journal-title":"Res Immunol"},{"key":"bib51","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"key":"bib52","first-page":"707","article-title":"The development of an experimental model of subretinal neovascularization in disciform macular degeneration","volume":"77","author":"Ryan","year":"1979","journal-title":"Trans Am Ophthalmol Soc"},{"key":"bib53","first-page":"e53502","article-title":"A mouse model for laser-induced choroidal neovascularization","volume":"106","author":"Shah","year":"2015","journal-title":"J Vis Exp"},{"key":"bib54","doi-asserted-by":"publisher","first-page":"e0132643","DOI":"10.1371\/journal.pone.0132643","article-title":"Optimization of an image-guided laser-induced choroidal neovascularization model in mice","volume":"10","author":"Gong","year":"2015","journal-title":"PLoS One"},{"key":"bib55","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1677\/joe.1.05876","article-title":"Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob\/ob mice","volume":"185","author":"Green","year":"2005","journal-title":"J Endocrinol"},{"key":"bib56","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"bib57","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"bib58","doi-asserted-by":"publisher","first-page":"106320","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol Res"},{"key":"bib59","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00125-017-4491-0","article-title":"Development and characterisation of a novel glucagon like peptide-1 receptor antibody","volume":"61","author":"Biggs","year":"2018","journal-title":"Diabetologia"},{"key":"bib60","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1111\/bph.15059","article-title":"Exendin-4, a GLP-1 receptor agonist regulates retinal capillary tone and restores microvascular patency after ischaemia-reperfusion injury","volume":"177","author":"Zhai","year":"2020","journal-title":"Br J Pharmacol"},{"key":"bib61","doi-asserted-by":"publisher","first-page":"4488","DOI":"10.1172\/JCI90699","article-title":"TNF regulates transcription of NLRP3 inflammasome components and inflammatory molecules in cryopyrinopathies","volume":"127","author":"McGeough","year":"2017","journal-title":"J Clin Invest"},{"key":"bib62","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/nm.2717","article-title":"NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components","volume":"18","author":"Doyle","year":"2012","journal-title":"Nat Med"},{"key":"bib63","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1124\/pr.115.011395","article-title":"Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes","volume":"68","author":"Graaf","year":"2016","journal-title":"Pharmacol Rev"},{"key":"bib64","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.metabol.2013.04.010","article-title":"GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways","volume":"62","author":"Aronis","year":"2013","journal-title":"Metabolism"},{"key":"bib65","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.bbrc.2013.03.053","article-title":"Evaluation of the in vitro and in vivo angiogenic effects of exendin-4","volume":"434","author":"Kang","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"bib67","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"bib68","doi-asserted-by":"publisher","first-page":"101351","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol Metab"},{"key":"bib66","volume-title":"Product monograph: including patient medication information","author":"Novo Nordisk Canada Inc","year":"2020"}],"container-title":["Investigative Ophthalmology & Visual Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2802968","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:31:58Z","timestamp":1791927118000},"score":1,"resource":{"primary":{"URL":"https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2802968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1167\/iovs.66.5.15","relation":{},"ISSN":["1552-5783"],"issn-type":[{"value":"1552-5783","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,7]]}}}